I don’t get offended easily, but implying that my content is responsible for somebody’s murder is pretty offensive…and tasteless. Vinay usually crusades against baseless claims with no evidence. I guess this one doesn’t count.

Well that explains a lot

Well, well, this is quite a story that I had not known about. Re: PLATO trial and ticagrelor bmj.com/content/387/bm… Thoughts welcome.

Merry Christmas to evidence based medicine 🎄🎁💉👀

1. Today the Federal Circuit rejected Teva's bid to list device patents for inhalers in the Orange Book. Practically this means that drug makers can't list patents for things like inhaler caps to block generic rivals from the market & keep prices high. A big win for Americans.

Heart failure with preserved ejection fraction is noted for symptoms of heart failure, LVEF of at least 50%, and cardiac or structural abnormalities. Treatment includes diuretics and SGLT2 inhibitors. Learn more: nej.md/4h41K6k

🧵1/ Last year, a thoughtful reply to our JAMA article sent me down a rabbit hole on CVD prevention. Should statins be prescribed less or more often? Available OTC? Added to the water supply?? Let’s talk trials, thresholds, and tradeoffs!

The 2025 ACS guideline synthesizes new evidence since the 2013 STEMI and 2014 NSTEMI guidelines and the 2015 focused update on primary PCI in STEMI. This guideline was developed with @ACCInTouch in collaboration with and endorsed by Emergency Physicians NAEMSP SCAI

Presented at #ACC25: Among older patients undergoing TAVI, dapagliflozin led to a lower incidence of a composite of death from any cause or worsening of heart failure than standard care at 1 year. Full DapaTAVI trial results: nej.md/4kSIc7L Editorial: Aortic Stenosis

Last year we sued the 3 largest pharmacy benefit managers for illegal tactics that inflate the cost of insulin & other drugs. FTC has now indefinitely paused the case. This follows the White House's unlawful attempt to fire Commissioners Bedoya & Slaughter. A gift to the PBMs.

Reevaluating Beta-Blocker Recommendations Post-Myocardial Infarction: Perspective on the 2025 Guideline Update: JACC Journals 🥸Commentary on the guidelines - early beta blocker use post MI - 😱Michael Nanna wrote extensively on this in older pts. 🥸Take a look 👇👇👇

If you take Entresto, we now have the generic and it starts at $33.75 ! It's probably lower than your deductible or Coinsurance. So check it out with your doctor !

Presented at #ESCCongress: In patients with cardiovascular disease and an implantable cardioverter–defibrillator, increasing potassium levels to the high-normal range reduced the risk of arrhythmia events, hospitalizations, and death. Full POTCAST trial results:

Presented at #ESCCongress: In patients with heart failure and reduced ejection fraction who were receiving guideline-directed medical therapy, digitoxin lowered the risk of death or hospitalization for heart failure as compared with placebo. Full DIGIT-HF phase 4 trial results:

Presented at #ESCCongress: Among patients with myocardial infarction and a left ventricular ejection fraction of more than 40%, beta-blockers did not lead to a lower incidence of death, reinfarction, or hospitalization for heart failure than no beta-blocker therapy. Full REBOOT

Presented at #ESCCongress: In patients with chronic coronary syndrome taking oral anticoagulants, adding aspirin led to higher risks of cardiovascular events, major bleeding, and death from any cause than anticoagulation alone. Full AQUATIC trial: nej.md/45AU4Wp

The AQUATIC trial may be the most definitive trial of #ESCCOngress The common combo of ASA and OAC for pts with CAD/stent and AF is clearly been harming people. Lots. MACE worse, Death worse, Bleeding way worse. STOP THE ASA when on OAC nejm.org/doi/full/10.10…

Biggest move today in clinic: Stopping ASA in pts on DOAC AQUATIC = most important trial of the year. medscape.com/viewarticle/aq…

I’m signing SB 41 to lower health care costs for all Californians. Alongside the 2025 budget and CalRx, this bill marks the most aggressive effort in the nation to drive down prescription drug prices, boost transparency, and ensure savings reach consumers and families.

Presented at #AHA25: In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. Full ADAPT